Welcome to the CED Clinic Weekly Literature Radar for September 20, 2026. This weekly index aggregates and translates 14 newly published biomedical studies, clinical trial protocols, open-access preprints, and health regulatory filings. By tracking multi-repository biomedical literature across PubMed, Europe PMC, ClinicalTrials.gov, and OpenAlex, CED Clinic provides patients, clinicians, and researchers with objective, evidence-grounded tracking of emerging science without overstating preliminary findings.

Each indexed report is examined for study design, sample size, quantified outcomes, and direct clinical applicability. Translating primary data into clear clinical perspectives empowers healthcare providers and patients to make informed, collaborative decisions about medical cannabis and related therapies.

Mainstream Media Claim: News reports frequently frame findings like “Nanostructured lipid carriers for intranasal cannabidiol delivery in D” as immediate therapeutic breakthroughs or universal treatment warnings without context.

Primary PubMed / Journal Evidence: Analysis of published data in PubMed provides verified cohort measurements and specific outcome markers. Systematic trial evaluation demonstrates distinct endpoints that clarify dosage boundaries, response rates, and tolerability profiles.

Dr. Caplan’s Clinical Verdict: Preliminary and single-center findings must be interpreted within their exact methodological boundaries. While providing valuable mechanistic and observational signals, they do not replace individualized clinical counseling, careful titration, or established safety protocols.

1. Nanostructured lipid carriers for intranasal cannabidiol delivery in Dravet and Lennox-Gastaut syndromes: bridging preclinical promise to clinical translation.

Source: PubMed (September 20, 2026) | PMID: 42751849 | DOI: 10.1080/20415990.2026.2731738: Primary Link

Study Design & Cohort: This is a narrative review of the preclinical and translational literature on cannabidiol (CBD) delivered by nanostructured lipid carriers (NLCs) via the intranasal route for Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS). The authors searched PubMed, Scopus, Web of Science, and Google Scholar for studies published through March 2026, and synthesized data from animal models, pharmacokinetic studies, and formulation research rather than reporting a new patient cohort or randomized trial.

Primary Findings: Across preclinical studies, intranasal NLC-CBD increased brain CBD concentrations, improved brain-to-plasma ratios, and prolonged central exposure at lower doses compared with free CBD or oral CBD. The review also notes anticonvulsant activity in established seizure models, including pentylenetetrazol-induced convulsions, with faster brain delivery and reduced systemic exposure relative to conventional oral preparations.

Clinical Relevance: For my practice, the appeal here is practical, faster CNS delivery, lower first-pass metabolism, and the possibility of better seizure control with less systemic burden than oral CBD. If this platform reaches pediatric trials, dosing will need to be built around intranasal pharmacokinetics, nasal tolerability, age-specific anatomy, and interaction checks with common antiseizure drugs, especially in children already on polytherapy. For families managing DS or LGS, a treatment that may act faster and fit more easily into daily care could meaningfully improve seizure burden and quality of life, but it still needs rigorous pediatric safety and efficacy data before routine use.

2. Cocaine, cannabis, champagne-pharmacological and toxicological references in the lyrics of the German rapper Haftbefehl: a content analysis.

Source: PubMed (September 20, 2026) | PMID: 42733016 | DOI: 10.1007/s00210-026-05904-7: Primary Link

Study Design & Cohort: This was a content analysis of the lyrics from seven studio albums by the German rapper Haftbefehl, released between 2010 and 2022. The dataset included 121 songs obtained from genius.com, and the investigators coded explicit and contextual references to psychotropic substances, slang terms, and references to drug use or trafficking across pharmacologic classes.

Primary Findings: Substance-related references were highly prevalent across the corpus, with cocaine mentioned in 82.6% of songs, cannabis in 52.9%, and alcohol in 38.0%. References to μ-opioid receptor agonists appeared in 9.1% of songs and amphetamine-type substances in 7.4%, while benzodiazepines were not referenced at all. The lyrics also contained a wide range of cocaine-related slang terms, and exploratory cross-album comparisons were performed descriptively.

Clinical Relevance: From a clinical perspective, this kind of lyrical exposure matters because it normalizes drug language for adolescents and young adults, especially around cocaine and cannabis. In practice, I would use music and media references as an opening for brief substance-use screening, counseling on stimulant and cannabis risks, and discussion of how repeated cultural cues can shape perceived acceptability of use. For patients already using substances, these references can help frame conversations about triggers, peer influence, and harm reduction in a language that feels familiar to them.

3. Proof-of-concept trial of PP-01 for mitigating cannabis withdrawal syndrome in participants with cannabis use disorder.

Source: PubMed (September 20, 2026) | PMID: 42717263 | DOI: 10.1111/ajad.70202: Primary Link

Study Design & Cohort: This was a Phase 1b/2a randomized, double-blind, placebo-controlled, crossover inpatient trial conducted over 5 nights. Fourteen adults with moderate to severe cannabis use disorder, daily or near-daily cannabis use of at least 1 gram per day, and a history of cannabis withdrawal received PP-01, a combination of nabilone and gabapentin, versus placebo.

Primary Findings: PP-01 significantly reduced withdrawal symptom severity within 10 hours of the first dose (p =.0222) and reduced withdrawal bothersomeness within 4 hours (p =.0063). Sleep quality and cannabis craving improved after the first dose through discharge, objective withdrawal measures also improved significantly, and treatment was well tolerated with only mild adverse events and no serious adverse events.

Clinical Relevance: For patients with cannabis use disorder who repeatedly fail quit attempts because of withdrawal, this combination approach offers a practical inpatient bridge through the first days of abstinence. The signal for rapid improvement in sleep, craving, and withdrawal burden is clinically meaningful, especially because there is no FDA-approved medication for cannabis withdrawal syndrome. In practice, I would think about medication interactions and sedation risk from gabapentin and nabilone, then match the regimen to patients with severe withdrawal, insomnia, and high relapse risk.

4. Role Status Changes During Emerging Adulthood and Their Association with Substance Use, Mental Health, and Well-Being Outcomes over a 4-Year Period.

Source: PubMed (September 20, 2026) | PMID: 42714793 | DOI: 10.1007/s11121-026-01970-8: Primary Link

Study Design & Cohort: This was a longitudinal cohort study of 2,174 young people followed annually from 2008, with analyses centered on wave 11 at a mean age of 21 and wave 14 at a mean age of 25. Investigators used latent transition analysis to classify combinations of role status changes, including living situation, education, employment, and relationship status, and then tested associations with substance use, mental health, and life satisfaction outcomes across 4 years. They also examined differences in transition patterns by race and ethnicity and by sexual and/or gender diverse status.

Primary Findings: Young people who transitioned into the Launched class, regardless of their starting role pattern, had lower depression and anxiety scores, a lower likelihood of alcohol use disorder and cannabis use disorder, and higher life satisfaction. In contrast, those who transitioned into the Extended Transition class had the poorest outcomes across these measures. Hispanic participants and those with sexual and/or gender diverse identity were more likely to be in the Extended Transition class.

Clinical Relevance: In practice, this study supports looking beyond a single milestone such as school completion or employment, and instead assessing the full pattern of role changes when counseling young adults. Patients who remain in prolonged transition states may need closer screening for depression, anxiety, alcohol use, and cannabis use, along with support for housing, education, work, and relationship stability. For me, the key point is that a nontraditional path can still be healthy, but persistent instability deserves active follow-up and targeted support, especially for Hispanic and SGD young adults.

5. Whole-exome sequencing in individuals with obsessive-compulsive disorder and chronic tic disorders identifies 36 large-effect risk genes.

Source: PubMed (September 20, 2026) | PMID: 42680906 | DOI: 10.1038/s41593-026-02419-5: Primary Link

Study Design & Cohort: This was a whole-exome sequencing study of 3,964 individuals with obsessive-compulsive disorder, chronic tic disorders, or both, including 2,418 trios. The investigators assessed de novo and rare protein-damaging variants and applied gene-level analyses to identify high-confidence risk genes, with follow-up transcriptomic and network analyses across neurodevelopmental tissues.

Primary Findings: Cases showed an excess of de novo and rare protein-damaging mutations, and the analysis identified 36 high-confidence risk genes at a false discovery rate below 0.1. Four previously recognized genes were confirmed, CELSR3, CHD8, SCUBE1, and WWC1, and four genes overlapped with OCD GWAS loci, BRWD1, CELSR3, QRICH1, and SYNE1. Risk genes were shared across OCD, CTDs, and other neurodevelopmental conditions, with increased expression in postnatal cerebellum, prenatal cortex, postnatal cortex, and striatum.

Clinical Relevance: For clinicians, this supports OCD and chronic tic disorders as genetically complex neurodevelopmental conditions with meaningful overlap in biology, which fits the frequent clinical co-occurrence we see in practice. The gene expression pattern points toward cerebellar, cortical, and striatal circuitry, which may help frame future treatment targets beyond symptom control alone. At present, this is not a dosing paper, but it strengthens the rationale for careful phenotyping, family history review, and referral for genetic counseling when OCD or tic symptoms cluster with broader neurodevelopmental features.

6. Effects of delta-9 tetrahydrocannabinol and cannabidiol on cognitive outcomes following acute use of cannabis for chronic pain.

Source: PubMed (September 20, 2026) | PMID: 42678518 | DOI: 10.1007/s00213-026-07157-x: Primary Link

Study Design & Cohort: This was a prospective, self-selected observational study of 183 adults using edible cannabis for chronic, non-specific low back pain. Participants were grouped by product type, CBD-dominant, THC-dominant, or mixed CBD to THC, and completed cognitive testing before use, 1 hour after use, and 2 hours after use across executive function, processing speed, memory, and verbal learning domains.

Primary Findings: At 1 hour post-use, the CBD group performed better than the CBD plus THC group on working memory. The CBD group also showed more stable verbal learning scores after use than the THC and CBD plus THC groups, while no significant effects were seen for executive function, episodic memory, or processing speed. Older age was associated with better working memory in the CBD group before use, and that association weakened across later timepoints.

Clinical Relevance: For patients using cannabis for chronic pain, this study suggests CBD-dominant edibles may carry less acute cognitive disruption than THC-containing products, especially for working memory and verbal learning. In practice, I would be cautious with THC-heavy formulations in patients who need to drive, work, or manage complex daily tasks, and I would favor the lowest effective dose with close attention to timing relative to cognitive demands. This also supports counseling patients that pain relief and cognition can move in different directions, so product selection matters as much as the decision to use cannabis at all.

7. Pilot study comparing the effects of high dose THC to high dose psilocybin and placebo in the set and setting of a classic psychedelic therapy session.

Source: PubMed (September 20, 2026) | PMID: 42649324 | DOI: 10.1007/s00213-026-07138-0: Primary Link

Study Design & Cohort: This was a double-blind, placebo-controlled, within-subject crossover pilot human laboratory study in 4 healthy adults aged 31 to 47 years, 3 of whom were women. Participants received oral placebo, psilocybin 25 mg, and oral Δ9-THC 25 mg, with 2 participants also receiving Δ9-THC 50 mg; Δ9-THC was given as either synthetic dronabinol or a whole-plant cannabis distillate extract containing 89.9% Δ9-THC. Subjective effects, cardiovascular measures, safety, and post-session drug identification were assessed under set and setting conditions modeled on a classic psychedelic therapy session.

Primary Findings: A 25 mg oral dose of Δ9-THC in both formulations produced a subjective experience similar to 25 mg psilocybin. Dronabinol was identified as a classic hallucinogen by both a psychedelic-naive participant and a psychedelic-experienced participant. The report also notes that 2 participants received 50 mg Δ9-THC, but the abstract does not provide separate quantitative outcome data for that dose.

Clinical Relevance: In practice, this small study tells me that oral THC at 25 mg can produce a psychedelic-like state in a therapy-style environment, so dose and context matter a great deal when patients use high-dose edibles or oral cannabinoids. I would counsel caution with oral THC products, especially in patients with anxiety, prior psychedelic exposure, or concurrent medications that can amplify sedation, tachycardia, or perceptual changes. For clinicians working with cannabinoid therapy, this supports careful titration, clear anticipatory guidance, and attention to the setting in which the medication is taken.

8. Prevalence of nicotine, alcohol, and cannabis use disorders among adults with chronic pain: Protocol for a systematic review and meta-analysis.

Source: PubMed (September 20, 2026) | PMID: 42647479 | DOI: 10.1371/journal.pone.0356365: Primary Link

Study Design & Cohort: This is a protocol for a systematic review and meta-analysis of adult chronic pain studies that report nicotine, alcohol, or cannabis use disorders, along with problematic use and co-use where available. The review will search PubMed, Embase, Web of Science Core Collection, CINAHL, and PsycINFO, with trained staff performing screening and data extraction across the eligible literature.

Primary Findings: No pooled results are reported in this protocol, because the paper describes the planned methods rather than completed analyses. The primary planned endpoint is pooled prevalence of nicotine, alcohol, and cannabis use disorders among adults with chronic pain, with problematic use as a secondary outcome and subgroup analyses planned to examine sources of heterogeneity.

Clinical Relevance: For pain practice, this review is aimed at defining how often nicotine, alcohol, and cannabis use disorders coexist with chronic pain, which matters when I am assessing adherence, function, sleep, mood, and medication safety. In real-world care, these data can help guide screening for substance use, counseling around cannabis and alcohol use, and treatment planning when patients are using multiple agents for pain relief or self-management.

9. Comparative efficacy of non-pharmacological interventions for individuals with cannabis use disorder: a systematic review and network meta-analysis protocol.

Source: PubMed (September 20, 2026) | PMID: 42627807 | DOI: 10.1371/journal.pone.0355941: Primary Link

Study Design & Cohort: This is a systematic review and frequentist network meta-analysis protocol of randomized controlled trials in individuals with cannabis use disorder. The planned comparisons include non-pharmacological interventions, such as psychosocial therapies and neurotherapy, versus waitlist, no-intervention, non-specific control, or another non-pharmacological intervention, with searches across PubMed, Embase, CENTRAL, and CINAHL. Pairs of reviewers will independently screen studies, extract data, assess risk of bias, and rate certainty with GRADE.

Primary Findings: No efficacy results are reported in this protocol because the review has not yet been completed. The prespecified primary outcomes are biochemically verified cannabis abstinence and self-reported days of cannabis use over the past 30 days, with acceptability measured by treatment retention and follow-up retention. Safety outcomes will include the overall incidence of intervention-related adverse events and serious adverse events.

Clinical Relevance: For clinicians, this project is designed to clarify which non-pharmacological approaches deserve priority when treating cannabis use disorder in real practice. The final network estimates, paired with GRADE certainty ratings, should help guide selection among psychosocial and neurobiological options based on abstinence, use reduction, retention, and safety. That kind of hierarchy is especially useful when counseling patients who prefer non-drug treatment or who need an adjunct to behavioral care.

10. Exploring the potential benefits of combining cannabidiol and beta-caryophyllene for neuropathic and inflammatory pain: A systematic review.

Source: PubMed (September 20, 2026) | PMID: 42753475 | DOI: 10.1016/j.phymed.2026.158798: Primary Link

Study Design & Cohort: This was a systematic review conducted according to PRISMA guidelines, using searches of Google Scholar, Web of Science, and PubMed from 2009 to 2026. The search yielded 31 records, 10 reports were screened for eligibility, and 5 preclinical studies met inclusion criteria, all examining cannabidiol (CBD) plus beta-caryophyllene (BCP) in rodent models of neuropathic and inflammatory pain.

Primary Findings: Across the included studies, the CBD and BCP combination consistently reduced neuropathic and inflammatory pain in rodent models. The review reports that the analgesic effect occurred without adverse outcomes linked to cannabinoid receptor 1 (CB1) activation, supporting a synergistic pain-relieving signal with fewer central cannabinoid effects.

Clinical Relevance: For practice, this combination is interesting because it points to a non-opioid, cannabinoid-based strategy for chronic pain with a lower likelihood of CB1-mediated psychoactive effects. In my view, CBD plus BCP may be worth watching for patients with neuropathic or inflammatory pain who need functional relief and who are sensitive to central cannabinoid side effects, while keeping in mind that these data are still preclinical and human dosing remains undefined. BCP is a common dietary terpene, so product selection, cannabinoid content, and interaction review with other sedating or metabolized medications still matter when translating this into care.

11. Comment on “Efficacy of cannabinoids for insomnia and sleep disturbance: A systematic review and meta-analysis of randomized controlled trials”.

Source: PubMed (September 20, 2026) | PMID: 42753382 | DOI: 10.1016/j.sleep.2026.109265: Primary Link

Study Design & Cohort: The provided source is a commentary on a systematic review and meta-analysis of randomized controlled trials evaluating cannabinoids for insomnia and sleep disturbance. The underlying evidence base included randomized controlled trials in patients with sleep complaints, with cannabinoid compounds assessed across the included studies.

Primary Findings: The abstract and data were not provided, so exact pooled effect sizes, confidence intervals, and endpoint-specific results cannot be extracted from the source text. The article title indicates that the review focused on efficacy outcomes for insomnia and sleep disturbance across randomized trials of cannabinoids.

Clinical Relevance: From a clinical standpoint, this topic matters because patients with insomnia often ask about cannabinoid products as a sleep aid, and the evidence base should be interpreted through the lens of dose, formulation, and next-day function. In practice, I would weigh any sleep benefit against sedation, cognitive effects, tolerance, and interactions with other CNS-active medications before recommending a cannabinoid trial.

12. Cannabinoid type 1 receptor availability imaging in attention-deficit/hyperactivity disorder using [18F]MK-9470 positron emission tomography: study protocol of the CB1-ADHD study.

Source: PubMed (September 20, 2026) | PMID: 42728455 | DOI: 10.1186/s41824-026-00322-7: Primary Link

Study Design & Cohort: This is a controlled study protocol using positron emission tomography with the CB1-selective radiotracer [18F]MK-9470 to measure cannabinoid type 1 receptor availability in ADHD. The planned sample includes three groups of 34 participants each: medication-naïve ADHD, methylphenidate-treated ADHD, and healthy controls, with plasma endocannabinoids and validated neuropsychological testing collected alongside imaging.

Primary Findings: No outcome data are reported in this protocol. The primary endpoint is striatal CB1 receptor distribution volume (VT), with secondary measures of CB1 availability in the prefrontal cortex and other ADHD-relevant regions, plasma anandamide and 2-arachidonoylglycerol, and attention and impulsivity scores. Group comparisons will use ANOVA with post-hoc testing, and correlations will assess relationships between imaging and behavioral measures.

Clinical Relevance: From a clinical standpoint, this study is aimed at defining whether the endocannabinoid system is a meaningful target in ADHD, especially in patients whose symptoms persist despite standard stimulant therapy. If CB1 signaling tracks with impulsivity or executive dysfunction, it could open the door to cannabinoid-based treatment strategies that are more tailored than current stimulant-only approaches. For now, the practical value is mechanistic, but the work may eventually help us think about treatment selection, symptom domains, and how prior methylphenidate exposure shapes neurobiology.

13. Physiological-behavioural discordance in paediatric perioperative anxiety assessment: a scoping review protocol.

Source: PubMed (September 20, 2026) | PMID: 42716682 | DOI: 10.1136/bmjopen-2026-123570: Primary Link

Study Design & Cohort: This is a scoping review protocol, not a primary clinical trial, designed to map published evidence on physiological-behavioural discordance in paediatric perioperative anxiety. The planned search will cover PubMed/MEDLINE, Embase, Web of Science Core Collection, CINAHL Complete, and PsycINFO from inception through 31 December 2025, with eligible studies including children aged 0 to 18 years in perioperative or analogous procedural settings. Included reports must pair a behavioural anxiety measure, such as mYPAS, mYPAS-SF, or STAI-C, with at least one concurrent physiological stress marker, including heart rate variability, salivary cortisol, salivary alpha-amylase, electrodermal activity, heart rate, or intraoperative nociception indices.

Primary Findings: No quantitative outcome data are reported in this protocol. The review will primarily examine perioperative anaesthesia induction, with procedural sedation, venipuncture, and dental settings analysed separately as a secondary stratum because their stress profiles differ from anaesthesia induction. Prespecified confounders for extraction include premedication exposure, regular home psychoactive medication use, including cannabinoids, and the time interval between behavioural and physiological sampling.

Clinical Relevance: For paediatric perioperative care, this work addresses a common bedside problem, a child can look calm on mYPAS-type observation while still showing a high autonomic stress response. In practice, that means I would want to pair behavioural scoring with physiologic markers when available, especially around induction, and I would pay close attention to timing, premedication, and home psychoactive medications because they can shift the signal. The end goal is a more complete anxiety assessment that can guide anxiolysis, family counseling, and perioperative planning for children whose distress is easy to miss on observation alone.

14. Cannabis and cannabinoids for the treatment of mental and substance use disorders and symptoms: A systematic review and meta-analysis of experimental and observational studies.

Source: PubMed (September 20, 2026) | PMID: 42617303 | DOI: 10.1016/j.psychres.2026.117380: Primary Link

Study Design & Cohort: This was a systematic review and meta-analysis registered in PROSPERO that searched CENTRAL, MEDLINE, Embase, and PsycINFO through May 2025. The authors included 82 experimental studies and 118 observational studies in adults with ADHD, anxiety, depression, PTSD, psychosis, Tourette syndrome, or alcohol, cannabis, opioid, or tobacco use disorders, and they assessed study quality with risk-of-bias methods and GRADE.

Primary Findings: In randomized trials, cannabinoids reduced anxiety symptoms with a standardized mean difference of -0.40 (95% CI, -0.57 to -0.23; I²=90%), and one small PTSD trial showed a larger effect with SMD -2.60 (95% CI, -4.58 to -0.62; n=20). Depression showed no meaningful benefit, SMD -0.20 (95% CI, -0.43 to 0.04; I²=91.6%), and cannabinoids worsened cannabis use disorder severity in one RCT, SMD 2.35 (95% CI, 1.49 to 3.21), while THC increased withdrawals due to adverse events, OR 2.78 (95% CI, 1.66 to 4.65).

Clinical Relevance: From a practical standpoint, I would not use cannabinoids as first-line treatment for anxiety, PTSD, depression, or substance use disorders based on this evidence base. If a patient is already using THC-containing products, I would watch closely for adverse effects and treatment discontinuation, especially in people with cannabis use disorder or complex psychiatric comorbidity. The signal for anxiety and PTSD is interesting, but the certainty is very low, so any consideration of cannabinoids should be cautious, individualized, and secondary to established therapies.

The current research cohort reflects diverse investigations spanning Nanostructured lipid carriers for intranasal canna, emphasizing rigorous study endpoints and reproducible methodologies across academic centers.

Synthesizing these findings alongside registered clinical trials gives clinicians and patients an objective framework to assess translational science without premature assumptions.

Tracking literature like Nanostructured lipid carriers for intranasal canna is most valuable when we look past the excitement to the actual endpoints and patient population.

Having verified data points gives us a steady, grounded baseline to discuss realistic expectations, safety, and personalized care.

Three Rules for Critical Reading